Literature DB >> 21772229

A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease.

Marieke E B Welzen1, Roger J M Brüggemann, J Merlijn Van Den Berg, Heleen W Voogt, Jos H Gilissen, Dasja Pajkrt, Nigel Klein, David M Burger, Adilia Warris.   

Abstract

Posaconazole (PSZ) may be an attractive alternative for antifungal prophylaxis in children with chronic granulomatous disease. Experience with PSZ in pediatric patients is limited, and no specific dose recommendations exist. A twice daily dosing algorithm based on allometric scaling (body-weight based) for PSZ results in adequate exposure and appears to be safe in children with chronic granulomatous disease.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21772229     DOI： 10.1097/INF.0b013e3182195808

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  15 in total

1.  Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Authors:  T Jancel; P A Shaw; C W Hallahan; T Kim; A F Freeman; S M Holland; S R Penzak
Journal:  J Clin Pharm Ther       Date:  2016-12-16       Impact factor: 2.512

2.  Common severe infections in chronic granulomatous disease.

Authors:  Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

Review 3.  Advances in the treatment of invasive neonatal candidiasis.

Authors:  Lorena Botero-Calderon; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Expert Opin Pharmacother       Date:  2015-04-05       Impact factor: 4.103

Review 4.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

5.  Case Report: Symptomatic Chronic Granulomatous Disease in the Newborn.

Authors:  Milica Miladinovic; Boris Wittekindt; Sebastian Fischer; Elise Gradhand; Steffen Kunzmann; Stefanie Y Zimmermann; Shahrzad Bakhtiar; Thomas Klingebiel; Rolf Schlösser; Thomas Lehrnbecher
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 6.  Fundament and Prerequisites for the Application of an Antifungal TDM Service.

Authors:  Roger J M Brüggemann; Rob E Aarnoutse
Journal:  Curr Fungal Infect Rep       Date:  2015

Review 7.  Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.

Authors:  Julie Autmizguine; Jeffrey T Guptill; Michael Cohen-Wolkowiez; Daniel K Benjamin; Edmund V Capparelli
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

Review 8.  Aspergillosis in Chronic Granulomatous Disease.

Authors:  Jill King; Stefanie S V Henriet; Adilia Warris
Journal:  J Fungi (Basel)       Date:  2016-05-26

Review 9.  Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.

Authors:  Lu Chen; Yan Wang; Tao Zhang; Ying Li; Ti Meng; Leichao Liu; Ruifang Hao; Yalin Dong
Journal:  BMC Infect Dis       Date:  2018-04-02       Impact factor: 3.090

Review 10.  Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease.

Authors:  Maria A Slack; Isaac P Thomsen
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-09       Impact factor: 3.164
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.